Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies

(2016) Amy Jo Chien et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

(2016) V. M. Macaulay et al.   CLINICAL CANCER RESEARCH

Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway

(2016) Jun Li et al.   TUMOR BIOLOGY

Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells

(2016) Aleksandra M. Ochnik et al.   NEOPLASIA

Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT–mTOR pathway

(2015) Miao Deng et al.   ANTI-CANCER DRUGS

Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line

(2015) Ayunadirah Ayub et al.   BIOMEDICINE & PHARMACOTHERAPY

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

(2015) Oreekha Amin et al.   BMC CANCER

In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib

(2015) Ashok K. Chakraborty et al.   BREAST CANCER RESEARCH AND TREATMENT

IGF1 regulates PKM2 function through Akt phosphorylation

(2015) Barbara Salani et al.   CELL CYCLE

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

(2015) W. J. Gradishar et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

(2015) W. T. Iams et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies

(2015) S. Gupta et al.   CLINICAL CANCER RESEARCH

Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer

(2015) Deepa Subramaniam et al.   CURRENT CANCER DRUG TARGETS

Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours

(2015) S.A. Piha-Paul et al.   EUROPEAN JOURNAL OF CANCER

Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt

(2015) Abeer Bahnassy et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

EGFR and MEK Blockade in Triple Negative Breast Cancer Cells

(2015) Monica Rosaria Maiello et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis

(2015) Hogyoung Kim et al.   Journal of Translational Medicine

Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells

(2015) P. Fan et al.   MOLECULAR CANCER RESEARCH

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

(2015) M. P. Sanderson et al.   MOLECULAR CANCER THERAPEUTICS

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology

Better Together: Targeted Combination Therapies in Breast Cancer

(2015) Elisa Zanardi et al.   SEMINARS IN ONCOLOGY

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease

(2015) Murugan Kalimutho et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

(2015) J. R. Devlin et al.   Cancer Discovery

FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells

(2015) LaTonia Taliaferro-Smith et al.   Oncotarget

A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties

(2015) Melissa R. Pitman et al.   Oncotarget

Biologic Roles of Estrogen Receptor-βand Insulin-Like Growth Factor-2 in Triple-Negative Breast Cancer

(2015) Nalo Hamilton et al.   Biomed Research International

Insulin-like Growth Factor-Dependent Proliferation and Survival of Triple-Negative Breast Cancer Cells: Implications for Therapy

(2015) Zoë Davison et al.   NEOPLASIA

Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

(2014) Xing-Ming Ye et al.   BMC CANCER

Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer

(2014) Julie M. Madden et al.   BREAST CANCER RESEARCH AND TREATMENT

Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells

(2014) M Mancini et al.   BRITISH JOURNAL OF CANCER

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

(2014) G Peiró et al.   BRITISH JOURNAL OF CANCER

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

(2014) Daruka Mahadevan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells

(2014) Ram K. Singh et al.   CANCER LETTERS

Dsh Homolog DVL3 Mediates Resistance to IGFIR Inhibition by Regulating IGF-RAS Signaling

(2014) S. Gao et al.   CANCER RESEARCH

IGF-I Regulates Redox Status in Breast Cancer Cells by Activating the Amino Acid Transport Molecule xC−

(2014) Yuzhe Yang et al.   CANCER RESEARCH

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

(2014) Helen King et al.   CANCER TREATMENT REVIEWS

Breast Cancer: Epidemiology and Etiology

(2014) ZiQi Tao et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

SOM230: A New Therapeutic Modality for Cushing's Disease

(2014) Ian Lewis et al.   CHIMIA

Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

(2014) P. Haluska et al.   CLINICAL CANCER RESEARCH

Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K-Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma

(2014) M. H. Wong et al.   CLINICAL CANCER RESEARCH

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

(2014) S. Di Cosimo et al.   CLINICAL CANCER RESEARCH

Insulin-Like Growth Factors, Insulin, and Growth Hormone Signaling in Breast Cancer: Implications for Targeted Therapy

(2014) Heather Beckwith et al.   Endocrine Practice

Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes In Vitro and in Male C57BL/6 Mice

(2014) Matei Mireuta et al.   ENDOCRINOLOGY

Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer

(2014) Anton G.T. Terwisscha van Scheltinga et al.   EUROPEAN JOURNAL OF CANCER

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

(2014) Claire Corcoran et al.   Molecular Cancer

Ligand-Mediated Endocytosis and Trafficking of the Insulin-Like Growth Factor Receptor I and Insulin Receptor Modulate Receptor Function

(2014) Alaide Morcavallo et al.   Frontiers in Endocrinology

Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor

(2013) I. McCaffery et al.   CLINICAL CANCER RESEARCH

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells

(2013) Yong Weon Yi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

(2013) Gary K Schwartz et al.   LANCET ONCOLOGY

Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

(2013) A. Pavlicek et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Insulin-like Growth Factor-Binding Protein-3 Signaling through Sphingosine Kinase-1 Sensitizes Triple-Negative Breast Cancer Cells to EGF Receptor Blockade

(2013) J. L. Martin et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin

(2013) K. Friedbichler et al.   MOLECULAR CANCER THERAPEUTICS

MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

(2013) J. B. Fitzgerald et al.   MOLECULAR CANCER THERAPEUTICS

Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R

(2013) Lulu Farhana et al.   PLoS One

Stromal EGF and IGF-I Together Modulate Plasticity of Disseminated Triple-Negative Breast Tumors

(2013) Z. Castano et al.   Cancer Discovery

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

(2012) H. L. Kindler et al.   ANNALS OF ONCOLOGY

Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition

(2012) Rebecca Croasdale et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours

(2012) Brigid C. Browne et al.   BREAST CANCER RESEARCH AND TREATMENT

Role of epidermal growth factor receptor in breast cancer

(2012) Hiroko Masuda et al.   BREAST CANCER RESEARCH AND TREATMENT

Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

(2012) A Gallardo et al.   BRITISH JOURNAL OF CANCER

Molecular Targets of FTY720 (Fingolimod)

(2012) M.R. Pitman et al.   CURRENT MOLECULAR MEDICINE

Biochemical Characterization of Individual Human Glycosylated pro-Insulin-like Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with Cancer

(2012) Sameer A. Greenall et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pharmacokinetics and Pharmacodynamics of Figitumumab, a Monoclonal Antibody Targeting the Insulin-Like Growth Factor 1 Receptor, in Healthy Participants

(2012) Donghua Yin et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer

(2012) Yuzhe Yang et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?

(2012) D. Yee   JNCI-Journal of the National Cancer Institute

BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer

(2012) N. Awasthi et al.   MOLECULAR CANCER THERAPEUTICS

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents

(2012) M Z Lin et al.   ONCOGENE

Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody

(2012) Jun Gyu Kim et al.   PLoS One

Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine

(2011) Amit Khatri et al.   AAPS Journal

Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer

(2011) X. Hou et al.   CANCER RESEARCH

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions

(2011) Bolin Liu et al.   CELL CYCLE

Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer

(2011) F. Pettersson et al.   CLINICAL CANCER RESEARCH

Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo

(2011) Naito Kurio et al.   EXPERIMENTAL CELL RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Factors influencing the inhibition of protein kinases

(2011) Marielle Brockhoff et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

(2011) Jianying Dong et al.   mAbs

The IGF Pathway Regulates ERα through a S6K1-Dependent Mechanism in Breast Cancer Cells

(2011) Marc A. Becker et al.   MOLECULAR ENDOCRINOLOGY

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Triple negative breast cancer: unmet medical needs

(2010) Sumanta Kumar Pal et al.   BREAST CANCER RESEARCH AND TREATMENT

Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma

(2010) Hermien Hartog et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

(2010) Denis Drygin et al.   CANCER RESEARCH

High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy

(2010) B. C. Litzenburger et al.   CLINICAL CANCER RESEARCH

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

(2010) T. M. Pitts et al.   CLINICAL CANCER RESEARCH

Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer

(2010) E. Rozengurt et al.   CLINICAL CANCER RESEARCH

Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics

(2010) M.R. Pitman et al.   CURRENT CANCER DRUG TARGETS

Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma

(2010) Gloria Peiró et al.   MODERN PATHOLOGY

Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo

(2010) Yin-He Wang et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts

(2010) Y. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Molecular Stratification of Triple-Negative Breast Cancers

(2010) C. M. Perou   ONCOLOGIST

Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia

(2010) David L. Kleinberg et al.   Pituitary

Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy

(2010) Neil K. Taunk et al.   RADIOTHERAPY AND ONCOLOGY

Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets

(2009) Nahum Sonenberg et al.   CELL

Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo

(2009) X. Zeng et al.   CLINICAL CANCER RESEARCH

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease

(2009) Antonino Belfiore et al.   ENDOCRINE REVIEWS

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

(2009) Mark J Mulvihill et al.   Future Medicinal Chemistry

Potentiation of Growth Factor Signaling by Insulin-like Growth Factor-binding Protein-3 in Breast Epithelial Cells Requires Sphingosine Kinase Activity

(2009) Janet L. Martin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

(2009) J. M. Carboni et al.   MOLECULAR CANCER THERAPEUTICS

High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

(2009) Yixuan Gong et al.   PLoS One

Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone

(2009) Hugh McTavish et al.   Translational Research

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

(2008) J. H. Law et al.   CANCER RESEARCH

Bidirectional Crosstalk between Leptin and Insulin-like Growth Factor-I Signaling Promotes Invasion and Migration of Breast Cancer Cells via Transactivation of Epidermal Growth Factor Receptor

(2008) N. K. Saxena et al.   CANCER RESEARCH

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

(2008) F. Huang et al.   CANCER RESEARCH

Dual Tyrosine Kinase Inhibitor for Focal Adhesion Kinase and Insulin-like Growth Factor-I Receptor Exhibits Anticancer Effect in Esophageal Adenocarcinoma In vitro and In vivo

(2008) N. Watanabe et al.   CLINICAL CANCER RESEARCH

Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer

(2008) J. Matsubara et al.   CLINICAL CANCER RESEARCH

Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis

(2008) Chad J. Creighton et al.   JOURNAL OF CLINICAL ONCOLOGY

Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer

(2008) Dedra H. Fagan et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Principles of bioactive lipid signalling: lessons from sphingolipids

(2008) Yusuf A. Hannun et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer

(2008) Daisuke Takahari et al.   ONCOLOGY